Back to Search
Start Over
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.
- Source :
- Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA509-LBA509, 83p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 42
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 177675902
- Full Text :
- https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA509